July 25, 2016
Recommended Topic Related To:


"Jan. 14, 2013 -- Just how long should that pesky cough last?

The answer, according to most doctors, is close to 18 days. Yet many people with a cough get antsy after about five to nine days, a new study shows.

“Coughs last "...



Vituz Side Effects Center

Medical Editor: John P. Cunha, DO, FACOEP

Last reviewed on RxList 4/7/2016

Vituz (hydrocodone bitartrate and chlorpheniramine maleate) is a combination of an opioid antitussive (anti-cough) and an antihistamine indicated for the treatment and relief of cough and symptoms associated with upper respiratory allergies or a common cold for adults 18 years of age and older. Vituz is available in generic form. Common side effects of Vituz include:

In patients 18 years and older, Vituz is dosed as 5 mL every 4 to 6 hours as needed, not to exceed 4 doses in 24 hours. Vituz should not be used to treat patients younger than 18 years of age. Vituz may interact with opioids, antihistamines, antipsychotics, anti-anxiety agents, other CNS depressants, MAOIs, or tricyclic antidepressants. Tell your doctor all medications and supplements you use. Vituz has not been studied in pregnant women. Caution should be exercised when Vituz is administered to nursing mothers. Hydrocodone and chlorpheniramine, two components of Vituz, are known to be excreted in human milk.

Our Vituz (hydrocodone bitartrate and chlorpheniramine maleate) Side Effects Drug Center provides a comprehensive view of available drug information on the potential side effects when taking this medication.

This is not a complete list of side effects and others may occur. Call your doctor for medical advice about side effects. You may report side effects to FDA at 1-800-FDA-1088.

What is Prescribing information?

The FDA package insert formatted in easy-to-find categories for health professionals and clinicians.

Vituz FDA Prescribing Information: Side Effects
(Adverse Reactions)


Use of hydrocodone bitartrate, a semisynthetic opioid, may result in the following:

Use of chlorpheniramine, an antihistamine, may result in:

  • Decreased mental alertness with impaired mental and/or physical abilities [see WARNINGS AND PRECAUTIONS]

The following adverse reactions have been identified either during clinical trials of hydrocodone bitartrate and/or chlorpheniramine maleate or during their use post-approval. Because these reactions may be reported voluntarily from a population of uncertain size, it is not always possible to reliably estimate their frequency or establish a causal relationship to drug exposure.

The most common adverse reactions of Vituz Oral Solution include: Sedation, somnolence, mental clouding, lethargy, impairment of mental and physical performance, anxiety, fear, dysphoria, dizziness, nausea, psychic dependence, mood changes; blurred, double, or other visual disturbances; confusion, headache, euphoria, facial dyskinesia, feeling faint, lightheadedness, agitation, irritability, tremor.

Other adverse reactions include:

Respiratory: Dryness of the pharynx and respiratory passages, occasional tightness of the chest, laryngismus, wheezing, or troubled breathing.

Gastrointestinal System: Nausea and vomiting (more frequent in ambulatory than in recumbent patients), constipation, abdominal distension, abdominal pain, acute pancreatitis, dry mouth, dyspepsia, epigastric distress, and/or loss of appetite.

Genitourinary System: Ureteral spasm, spasm of vesicle sphincters, urinary retention, dysuria, urinary frequency, urinary hesitancy.

Dermatological System: Skin rash, pruritus, erythema, urticaria, excessive perspiration.

Read the entire FDA prescribing information for Vituz (Hydrocodone Bitartrate and Chlorpheniramine Maleate) Oral Solution)

Report Problems to the Food and Drug Administration


You are encouraged to report negative side effects of prescription drugs to the FDA. Visit the FDA MedWatch website or call 1-800-FDA-1088.

Women's Health

Find out what women really need.